Stem Cell Therapeutics Announces Presentation of Modified REGENESIS Trial Results at the International Stroke Meeting
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Stem Cell Therapeutics Corp. has announced that Dr. Steven Cramer of the University of California at Irvine will be presenting results from the REGENESIS-LED trial at the International Stroke Conference, in Los Angeles, California.
The title of the poster presentation is entitled, "Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS Trial)."
"This presentation represents an important opportunity to review and discuss the modified REGENESIS trial for the first time with the stroke community." said Dr. Allen Davidoff, Chief Scientific Officer of SCT. "SCT looks forward to discussions of this trial at the meeting and integrating those discussions into our ongoing strategic planning for the NTx®-265 program in Acute Ischemic Stroke".
The title of the poster presentation is entitled, "Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS Trial)."
"This presentation represents an important opportunity to review and discuss the modified REGENESIS trial for the first time with the stroke community." said Dr. Allen Davidoff, Chief Scientific Officer of SCT. "SCT looks forward to discussions of this trial at the meeting and integrating those discussions into our ongoing strategic planning for the NTx®-265 program in Acute Ischemic Stroke".
